🧪 I. Basic Information on the Drug
Active Ingredients and Mechanism
Ebselen: An organic selenium compound that exerts anti-inflammatory and antioxidant effects by mimicking and activating glutathione peroxidase (GPx), protecting inner ear, retina, and nervous system cells from oxidative damage.
Indications: Primarily targeting Meniere’s Disease (MD), with extensions to noise-induced hearing loss and ototoxicity caused by platinum-based chemotherapy/aminoglycoside antibiotics (hearing loss, tinnitus, vertigo).
Dosage Form and Administration
Oral capsules, with a dosage of 400 mg (twice daily), standard treatment course of 28 days.
🔬 II. Key Clinical Trial Results
📅 Phase 1b/2b Study (Historical Data)
Significant improvement rate:
The phase 2b trial (126 patients) showed that after 8 weeks of treatment:
Low-frequency hearing improvement rate (pure tone audiometry PTA) reached 61% (vs. placebo group not specified).
Speech recognition rate (word test in noise WIN) improvement rate 68%, tinnitus loudness reduced by 30% (placebo group only 10%).
🚀 Phase 3 Trial (STOPMD-3, 2022-2024)
Trial Design:
Scale: 221 diagnosed Meniere’s disease patients, randomized double-blind control (SPI-1005 vs. placebo), follow-up 84 days, some patients entered a 12-month open-label extension (OLE).
Primary endpoints: Improvement rates of low-frequency hearing (LFPTA) and speech discrimination (WIN).
Core Results
| Indicator | SPI-1005 Group | Placebo Group | Improvement Magnitude | P-value |
|---|---|---|---|---|
| Low-frequency hearing improvement | 57.9% | 36.5% | ↑58.6% | 0.0037 |
| Speech discrimination improvement | 42.1% | 27.1% | ↑54.4% | 0.0336 |
| Dual-frequency hearing improvement* | 41.4% | 13.5% | ↑204.4% | <0.0001 |
Note: Dual-frequency refers to hearing improvement of ≥10 dB in two adjacent low-frequency ranges.
Long-term efficacy (OLE phase): Patients receiving continuous treatment for 12 months showed a further reduction in severity of symptoms such as tinnitus, vertigo, and ear fullness by ≥30% (p<0.001).
⏳ III. R&D Progress and Future Plans
Current Status:
The phase 3 trial completed follow-up of all patients on July 25, 2024, with topline results expected to be announced in December 2024, confirming achievement of primary endpoints.
Complete data analysis is scheduled for presentation at the American Academy of Otolaryngology-Head and Neck Surgery Winter Meeting from February 22-26, 2025.
Market Expectation:
SPI-1005 is the first new drug for Meniere’s disease to enter phase 3, having received FDA Fast Track designation. If approved smoothly, it is expected to be launched in the U.S. in 2025-2026.
Indication Expansion: Noise-induced hearing loss (phase 2), chemotherapy-induced ototoxicity (in co-development).
💎 Summary
SPI-1005 provides the first phase 3-validated pharmacological treatment for Meniere’s disease by targeting the oxidative damage mechanism in the inner ear, significantly improving hearing and speech function, with good long-term safety. Its mechanism also gives it potential in areas such as noise-induced deafness and chemotherapy-induced ototoxicity.
📚 Overview of Academic Literature and Reports Related to SPI-1005
1. “Final Results of the Phase III Clinical Trial of SPI-1005 for Meniere’s Disease (STOPMD-3)”
Published Source: Official Press Release from Sound Pharmaceuticals (December 2024)
Summary: Announced that SPI-1005 achieved the co-primary endpoints in 221 Meniere’s disease patients (low-frequency hearing improvement rate 57.9% vs. placebo group 36.5%, p=0.0037; speech discrimination improvement rate 42.1% vs. 27.1%, p=0.0336), with long-term open-label extension (OLE) showing sustained symptom relief ≥30%.
Key Data: Dual-frequency hearing improvement rate increased by 204.4% compared to the placebo group (p<0.0001), with good safety in the 12-month OLE phase.
2. “Mechanism and Phase III Trial Design of Oral Glutathione Peroxidase Mimetic SPI-1005 for Meniere’s Disease”
Published Source: Industry Analysis Report (Sohu, January 8, 2025)
Summary: Detailed analysis of the neuroprotective mechanism of SPI-1005’s active ingredient Ebselen (mimicking GPx enzyme), and overview of the STOPMD-3 trial design: 11 centers screened 254 patients, 221 randomized, including a 6-12 month OLE phase, making it the longest duration drug trial for Meniere’s disease to date.
3. “Phase II Trial Protocol for SPI-1005 Combined with Cochlear Implant”
Published Source: FDA IND Approval Announcement (Artery Network, May 20, 2024)
Summary: FDA approved SPI-1005 for a Phase II trial aimed at hearing protection after cochlear implantation. The trial design includes 40 patients, targeting reduction of residual hearing loss, in collaboration with medical device company MED-EL.
4. “Progress in Multi-Indication Development of SPI-1005 in Neurotological Diseases”
Comprehensive Report (2024-2025)
Summary: Summarizes preclinical and phase II data of SPI-1005 for noise-induced deafness, platinum-based chemotherapy ototoxicity, and aminoglycoside ototoxicity, emphasizing its potential as the first broad-spectrum neuroprotective agent to enter phase III.
📅 Academic Conference Reports
1. “Complete Data and Post-Analysis of the STOPMD-3 Trial”
Published Platform: American Academy of Otolaryngology-Head and Neck Surgery Winter Meeting (February 22-26, 2025, Orlando, Florida)
Preview Content: Dr. Lambert’s team will present detailed efficacy data, subgroup analyses, and long-term safety results from the phase III trial.
📖 Reference Book Chapters (Indirectly Related)
1. “Advanced Features of SPI Protocol and FPGA Implementation Details”
Publication Date: June 12, 2025 (CSDN Library)
Relevance Explanation: Although this book focuses on the technical implementation of the SPI communication protocol, the title contains “SPI” which overlaps with the drug name, requiring careful distinction. The content has no direct drug association, serving only as a technical reference.